Kelly C Allison, Ariana M Chao, Maija B Bruzas, Courtney McCuen-Wurst, Elizabeth Jones, Cooper McAllister, Kathryn Gruber, Robert I Berkowitz, Thomas A Wadden, Jena S Tronieri
{"title":"利拉鲁肽3.0 mg治疗暴食症的先导随机对照试验。","authors":"Kelly C Allison, Ariana M Chao, Maija B Bruzas, Courtney McCuen-Wurst, Elizabeth Jones, Cooper McAllister, Kathryn Gruber, Robert I Berkowitz, Thomas A Wadden, Jena S Tronieri","doi":"10.1002/osp4.619","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To assess the efficacy of liraglutide 3.0 mg, a glucagon-like peptide-1 (GLP-1) receptor agonist, for binge eating disorder (BED).</p><p><strong>Methods: </strong>Adults with a body mass index (BMI) ≥ 27 kg/m<sup>2</sup> enrolled in a pilot, 17-week double-blind, randomized controlled trial of liraglutide 3.0 mg/day for BED. The primary outcome was number of objective binge episodes (OBEs)/week. Binge remission, weight change, and psychosocial variables were secondary outcomes. Mixed effect models were used for continuous variables, and generalized estimating equations were used for remission rates.</p><p><strong>Results: </strong>Participants (<i>n</i> = 27) were 44.2 ± 10.6 years; BMI = 37.9 ± 11.8 kg/m<sup>2</sup>; 63% women; and 59% White and 41% Black. At baseline, the liraglutide group (<i>n</i> = 13) reported 4.7 ± 0.7 OBEs/week, compared with 3.0 ± 0.7 OBEs/week for the placebo group, <i>p</i> = 0.07. At week 17, OBEs/week decreased by 4.0 ± 0.6 in liraglutide participants and by 2.5 ± 0.5 in placebo participants (<i>p</i> = 0.37, mean difference = 1.2, 95% confidence interval 1.3, 2.0). BED remission rates of 44% and 36%, respectively, did not differ. Percent weight loss was significantly greater in the liraglutide versus the placebo group (5.2 ± 1.0% vs. 0.9 ± 0.7%, <i>p</i> = 0.005).</p><p><strong>Conclusion: </strong>Participants in both groups reported reductions in OBEs, with the liraglutide group showing clinically meaningful weight loss. A pharmacy medication dispensing error was a significant limitation of this study. Further research on liraglutide and other GLP-1 agonists for BED is warranted.</p>","PeriodicalId":19448,"journal":{"name":"Obesity Science & Practice","volume":"9 2","pages":"127-136"},"PeriodicalIF":1.9000,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/50/2f/OSP4-9-127.PMC10073825.pdf","citationCount":"3","resultStr":"{\"title\":\"A pilot randomized controlled trial of liraglutide 3.0 mg for binge eating disorder.\",\"authors\":\"Kelly C Allison, Ariana M Chao, Maija B Bruzas, Courtney McCuen-Wurst, Elizabeth Jones, Cooper McAllister, Kathryn Gruber, Robert I Berkowitz, Thomas A Wadden, Jena S Tronieri\",\"doi\":\"10.1002/osp4.619\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>To assess the efficacy of liraglutide 3.0 mg, a glucagon-like peptide-1 (GLP-1) receptor agonist, for binge eating disorder (BED).</p><p><strong>Methods: </strong>Adults with a body mass index (BMI) ≥ 27 kg/m<sup>2</sup> enrolled in a pilot, 17-week double-blind, randomized controlled trial of liraglutide 3.0 mg/day for BED. The primary outcome was number of objective binge episodes (OBEs)/week. Binge remission, weight change, and psychosocial variables were secondary outcomes. Mixed effect models were used for continuous variables, and generalized estimating equations were used for remission rates.</p><p><strong>Results: </strong>Participants (<i>n</i> = 27) were 44.2 ± 10.6 years; BMI = 37.9 ± 11.8 kg/m<sup>2</sup>; 63% women; and 59% White and 41% Black. At baseline, the liraglutide group (<i>n</i> = 13) reported 4.7 ± 0.7 OBEs/week, compared with 3.0 ± 0.7 OBEs/week for the placebo group, <i>p</i> = 0.07. At week 17, OBEs/week decreased by 4.0 ± 0.6 in liraglutide participants and by 2.5 ± 0.5 in placebo participants (<i>p</i> = 0.37, mean difference = 1.2, 95% confidence interval 1.3, 2.0). BED remission rates of 44% and 36%, respectively, did not differ. Percent weight loss was significantly greater in the liraglutide versus the placebo group (5.2 ± 1.0% vs. 0.9 ± 0.7%, <i>p</i> = 0.005).</p><p><strong>Conclusion: </strong>Participants in both groups reported reductions in OBEs, with the liraglutide group showing clinically meaningful weight loss. A pharmacy medication dispensing error was a significant limitation of this study. Further research on liraglutide and other GLP-1 agonists for BED is warranted.</p>\",\"PeriodicalId\":19448,\"journal\":{\"name\":\"Obesity Science & Practice\",\"volume\":\"9 2\",\"pages\":\"127-136\"},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2023-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/50/2f/OSP4-9-127.PMC10073825.pdf\",\"citationCount\":\"3\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Obesity Science & Practice\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1002/osp4.619\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Obesity Science & Practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/osp4.619","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
A pilot randomized controlled trial of liraglutide 3.0 mg for binge eating disorder.
Objective: To assess the efficacy of liraglutide 3.0 mg, a glucagon-like peptide-1 (GLP-1) receptor agonist, for binge eating disorder (BED).
Methods: Adults with a body mass index (BMI) ≥ 27 kg/m2 enrolled in a pilot, 17-week double-blind, randomized controlled trial of liraglutide 3.0 mg/day for BED. The primary outcome was number of objective binge episodes (OBEs)/week. Binge remission, weight change, and psychosocial variables were secondary outcomes. Mixed effect models were used for continuous variables, and generalized estimating equations were used for remission rates.
Results: Participants (n = 27) were 44.2 ± 10.6 years; BMI = 37.9 ± 11.8 kg/m2; 63% women; and 59% White and 41% Black. At baseline, the liraglutide group (n = 13) reported 4.7 ± 0.7 OBEs/week, compared with 3.0 ± 0.7 OBEs/week for the placebo group, p = 0.07. At week 17, OBEs/week decreased by 4.0 ± 0.6 in liraglutide participants and by 2.5 ± 0.5 in placebo participants (p = 0.37, mean difference = 1.2, 95% confidence interval 1.3, 2.0). BED remission rates of 44% and 36%, respectively, did not differ. Percent weight loss was significantly greater in the liraglutide versus the placebo group (5.2 ± 1.0% vs. 0.9 ± 0.7%, p = 0.005).
Conclusion: Participants in both groups reported reductions in OBEs, with the liraglutide group showing clinically meaningful weight loss. A pharmacy medication dispensing error was a significant limitation of this study. Further research on liraglutide and other GLP-1 agonists for BED is warranted.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
